proximab / HBL Hadasit Bio Holdings - LARVOL DELTA

Treprozumab and bevacizumab combined with three different interventional therapies (transcatheter arterial chemoembolization, transcatheter arterial chemoembolization, or transcatheter arterial chemoembolization) for unresectable hepatocellular carcinoma: a prospective, multicenter, randomized, non-controlled, phase II clinical study (ChiCTR) - P=N/A | N=90 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Institute); Sun Yat-sen University Cancer

New trial • Hepatocellular Cancer • Oncology • Solid Tumor